Esperion Therapeutics: Is Investor Enthusiasm Justified?
- Esperion is one of the best performing biotech stocks in 2017.
- Lead product candidate is progressing well.
- As a combination therapy, the potential to achieve blockbuster status is higher if approved.
By S. Mitra, MBA (ISB)
With the first half of 2017 completed, it is a good time to look at some of the best performing biotechnology stocks. The first half saw the iShares Nasdaq Biotech ETF (IBB) gain almost 17%. It must be noted though that most of the gains in the IBB have come mainly in the last few weeks. Having said that, the performance in the first half is still impressive. This performance though is dwarfed by the returns Esperion (ESPR) has generated for its investors in the first half of this year.
The full post is available to investor members only. Subscribe here.